CSL Behring - Prof. Heimburger Award
Research Grant - Coagulation

Prof. Dr. Norbert Heimburger

Professor Dr. Norbert Heimburger, a CSL Behring employee for over three decades, devoted his work to blood coagulation. During that time, he characterised and purified a large number of plasma proteins and was instrumental in making these available to the medical community as therapeutic options. One of his major contributions in this area was the development of virus-inactivated plasma products based on pasteurisation. Due to his determination and his constant interaction with leading haemophilia and coagulation specialists, Behring launched the first effectively virus-inactivated FVIII concentrate in 1981. Honoured with the Order of Merit of the Federal Republic of Germany in 1991, Professor Dr. Heimburger retired in 1991 but was still very much involved with CSL Behring as a Scientific Advisor until he passed away in September 2006.

CSL Behring named this grant CSL Behring - Prof. Heimburger Award to honour Professor Dr. Heimburger.

Funds available
CSL Behring will set up 5 global start-up grants of 20,000 euros each for the 2012 cycle. No matching funding is a prerequisite for this grant. The grants will be available for preclinical and/or clinical research in the area of coagulation.

Eligibility
The grants are targeted at investigators who hold an MD degree and have less than five years faculty experience in haemostasis.

To apply
Apply in one of these ways:

• Complete the online application form, save it, and email it to CSL Behring Medical Information
• Download an application and send it via post to the address below.

Medical Department
CSL Behring UK Ltd
Hayworth House
Haywards Heath
West Sussex
RH16 1DB

Applications - consisting of application form, current CV and research proposal (one-pager) must be postmarked no later than 7 October 2011 to be considered for the next cycle. Applications should be submitted to the address above and can also be submitted via e-mail.

All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation:

Thomas Abshire, MD
Blood Center of Wisconsin, Milwaukee, USA

Prof. Dr. Barbara Zieger
Universitätsklinik Freiburg, Zentrum für Kinderheilkunde, Freiburg, Germany

Claude Négrier, MD
Centre Régional de Traitement de L’Hemophilie, Hopital Edouard Herriot, Lyon, France

Patricia Casais, MD
Academia Nacional de Medicina, Fundacion de la Hemofilia, Buenos Aires, Argentina

The selection committee will review applications solely based on scientific merit. CSL Behring will notify the recipients in February 2012. The grants will be personally awarded at the CSL Behring - Prof. Heimburger Award Symposium in Marburg, Germany. All winners will be invited to present their supported projects to the Selection Committee. They will also meet previous winners and benefit from this global exchange platform for haemostasis among upcoming researchers.

More information
Grant statutes re available by downloading Research Grant Statutes. Note: To view this document, you must have Adobe Acrobat Reader installed. Reader is available as a free download from Adobe Systems Inc.

Enquiries
For enquiries regarding applications, policy and procedures information, please contact:

Medical Department
CSL Behring UK Ltd
Hayworth House
Haywards Heath
West Sussex
RH16 1DB
T: +44(0)1444 447 400
Email: CSL Behring Medical Information

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients’ lives, CSL Behring manufactures and markets a range of effective plasma-derived and recombinant products and related services. The company’s therapies are used in the treatment of rare diseases such as immune deficiency disorders, haemophilia, von Willebrand disease and other bleeding disorders. Other products are used for the prevention of haemolytic diseases in the newborn. The company also operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.co.uk.